Thomas Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and first CEO of Algeta ASA, a Norwegian biotech company that successfully developed and launched a radiopharmaceutical for prostate cancer. Furthermore, he was instrumental in Algeta’s 2007 IPO, as well as in the acquisition of the company by Bayer AG for USD 2.9B in 2014. Dr. Ramdahl has authored more than 40 publications and is a co-inventor of several patents. He gained his PhD in environmental chemistry from the University of Oslo in 1984 and an MSc in organic chemistry from the Norwegian Institute of Technology in 1979. He has also been engaged in executive training at the International Institute for Management Development (IMD) in Lausanne, Switzerland.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.